All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @kaseytwyman on TikTok · 14s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @kaseytwyman's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I'm the up with the only guy that I've been in between
  2. 0:04Oh, ride with the mob, homie, who I lost
  3. 0:07Check you and me, and we good job
  4. 0:09Earth in the name, and bullet to the chain
  5. 0:12Turn on, for the watch, and put it

@kaseytwyman's tirzepatide transformation, fact-checked

Kasey ♡

TikTok creator

716.7K viewsWatch on TikTok

Quick answer

This video promotes tirzepatide-driven weight loss through visual transformation, with no spoken medical claims but a clear aspirational message. Tirzepatide (Zepbound/Mounjaro) is FDA-approved for chronic weight management and type 2 diabetes, with clinical trial data showing up to 20.9% body weight reduction at the highest dose over 72 weeks. Patients considering this medication should be evaluated by a licensed clinician, as it carries a class labeling warning for thyroid C-cell tumor risk and requires monitoring for gastrointestinal, cardiovascular, and pancreatic effects.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @kaseytwyman's tirzepatide transformation, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@kaseytwyman's tirzepatide transformation, fact-checked" from Kasey ♡. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This video promotes tirzepatide-driven weight loss through visual transformation, with no spoken medical claims but a clear aspirational message.

The reason this review is not generic is the source wording and the canonical claim label "glp1 seeing my collarbone is such a new flex for me fyp t." In this clip, the useful excerpt is: "I'm the up with the only guy that I've been in between Oh, ride with the mob, homie, who I lost Check you and me, and we good job Earth in the name, and bullet to the chain Turn on, for the watch, and put it" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

82.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

This video promotes tirzepatide-driven weight loss through visual transformation, with no spoken medical claims but a clear aspirational message.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • This video promotes tirzepatide-driven weight loss through visual transformation, with no spoken medical claims but a clear aspirational message. Tirzepatide (Zepbound/Mounjaro) is FDA-approved for chronic weight management and type 2 diabetes, with clinical trial data showing up to 20.9% body weight reduction at the highest dose over 72 weeks. Patients considering this medication should be evaluated by a licensed clinician, as it carries a class labeling warning for thyroid C-cell tumor risk and requires monitoring for gastrointestinal, cardiovascular, and pancreatic effects.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) documented up to 20.9% body weight loss with tirzepatide 15mg over 72 weeks, making visible collarbone changes plausible for many patients.
  • 82.7% of participants on the highest tirzepatide dose in SURMOUNT-1 reported gastrointestinal side effects, a reality absent from celebratory social media posts.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) documented up to 20.9% body weight loss with tirzepatide 15mg over 72 weeks, making visible collarbone changes plausible for many patients.
  • 82.7% of participants on the highest tirzepatide dose in SURMOUNT-1 reported gastrointestinal side effects, a reality absent from celebratory social media posts.
  • SURMOUNT-4 (Aronne et al., 2024, JAMA) found that patients who discontinued tirzepatide regained approximately two-thirds of lost weight within 52 weeks, underscoring the chronic nature of obesity treatment.
  • Ozempic face is an informal term covering facial fat loss during GLP-1 therapy; it applies to multiple drugs and is not unique to semaglutide despite how the hashtag is used.
  • Tirzepatide is a dual GIP/GLP-1 receptor agonist, mechanistically different from semaglutide, and should not be grouped under semaglutide-specific branding without clarification.
  • GLP-1 medications require a licensed prescriber and ongoing clinical monitoring; they are not wellness products and carry FDA boxed warnings regarding thyroid C-cell tumor risk in rodent studies.
  • Compounded tirzepatide is not equivalent to FDA-approved Zepbound or Mounjaro; patients should discuss the differences with their provider before choosing a formulation.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @kaseytwyman actually say?

Honestly, not much, at least not in words that translate. The transcript captured in this video is essentially incoherent audio, likely background music lyrics rather than any spoken claim from the creator. What we do have is the caption: "Seeing my collarbone is such a new flex for me" paired with hashtags including #tirzepatide, #ozempicface, and #glp1community. So the message being sent to 716,000-plus viewers is visual and emotional: tirzepatide changed my body in a visible way, and I'm happy about it.

That's a real claim, even without a spoken word. The implication is that GLP-1 receptor agonist therapy, specifically tirzepatide, produced meaningful fat loss visible at the collarbone and face. That's worth examining carefully, because millions of people are making medical decisions based on exactly this kind of content.

Does the science back this up?

Yes, with important nuance. Tirzepatide does produce significant weight loss, and that loss does show up in the face and upper body. But the specifics matter more than the vibe.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that participants taking tirzepatide 15mg lost an average of 20.9% of body weight over 72 weeks. That is not subtle. Changes at that scale absolutely become visible at the collarbone, jaw, and face, which is what #ozempicface refers to informally. A 2023 analysis in Obesity Reviews (Rubino et al.) confirmed that facial fat redistribution is a real and commonly reported phenomenon with significant GLP-1-driven weight loss, though it is not universally welcomed by patients.

So the visual transformation implied here? Backed by data. The drug works. The question is always what else comes with it, and whether social media framing gives the full picture.

What did they get wrong (or right)?

To be fair, @kaseytwyman didn't make a specific medical claim here. There is no dosing advice, no promise of a cure, no misleading comparison between compounded and brand-name tirzepatide. It is a before-and-after emotional moment shared with a large audience. That restraint, intentional or not, matters.

What the video gets implicitly wrong is the framing of effortlessness. Hashtags like #thriving and #happy, combined with a striking physical transformation, contribute to a broader social media pattern that strips away the clinical reality. Tirzepatide causes nausea, vomiting, constipation, and gastrointestinal distress in a significant portion of users. The SURMOUNT-1 trial reported that 82.7% of participants on the highest dose experienced GI side effects. None of that is in the caption. The #wellnessjourney framing also sidesteps the fact that this is a prescription medication requiring medical supervision, not a lifestyle product.

The #ozempicface hashtag is also worth flagging. It conflates semaglutide (Ozempic/Wegovy) with tirzepatide (Mounjaro/Zepbound). These are different drugs with different mechanisms. Grouping them under one aesthetic hashtag is sloppy at best.

What should you actually know?

Tirzepatide is a dual GIP and GLP-1 receptor agonist, which is why its weight loss results tend to outperform older GLP-1 drugs in head-to-head data. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed that people who stopped tirzepatide regained most of their lost weight within a year. That is not a criticism of the drug. It reflects that obesity is a chronic condition requiring ongoing management, not a problem you solve once and flex about.

Visible changes like a more prominent collarbone are real outcomes for many patients. But they arrive alongside a medical regimen, regular check-ins, and side effect management. Social media posts, even honest ones, tend to show the result without the clinical process that produced it. If you are considering a GLP-1 medication because of content like this, talk to a licensed provider who can evaluate your full health picture before prescribing anything.

  • GLP-1 drugs are prescription medications, not wellness supplements.
  • Results vary significantly based on dose, adherence, diet, and individual metabolism.
  • Stopping the medication typically results in weight regain without lifestyle changes.
  • Facial fat loss, the so-called Ozempic face, is real but not universal.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Kasey ♡ · TikTok creator

716.7K views on this video

Seeing my collarbone is such a new flex for me... 😅 #fyp #tirzepatide #ozempicface #happy #thriving #glp1community #wellnessjourney

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about surmount-1 (jastreboff et al., 2022, nejm) documented up to 20.9%?

SURMOUNT-1 (Jastreboff et al., 2022, NEJM) documented up to 20.9% body weight loss with tirzepatide 15mg over 72 weeks, making visible collarbone changes plausible for many patients.

What does the video say about 82.7% of participants on the highest tirzepatide dose in surmount-1?

82.7% of participants on the highest tirzepatide dose in SURMOUNT-1 reported gastrointestinal side effects, a reality absent from celebratory social media posts.

What does the video say about surmount-4 (aronne et al., 2024, jama) found?

SURMOUNT-4 (Aronne et al., 2024, JAMA) found that patients who discontinued tirzepatide regained approximately two-thirds of lost weight within 52 weeks, underscoring the chronic nature of obesity treatment.

What does the video say about ozempic face?

Ozempic face is an informal term covering facial fat loss during GLP-1 therapy; it applies to multiple drugs and is not unique to semaglutide despite how the hashtag is used.

What does the video say about tirzepatide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist, mechanistically different from semaglutide, and should not be grouped under semaglutide-specific branding without clarification.

What does the video say about glp-1 medications require a licensed prescriber?

GLP-1 medications require a licensed prescriber and ongoing clinical monitoring; they are not wellness products and carry FDA boxed warnings regarding thyroid C-cell tumor risk in rodent studies.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Kasey ♡, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.